Search Results for: Ultrasuoni contro il cancro del pancreas

We read with great interest the study by Danpanichkul et al,1 which assessed the global burden of gastrointestinal cancers, including oesophagus, gastric, colorectal, liver, pancreas and biliary tract cancers, from 2000 to 2021. The study revealed that the burden of all types of cancers varies across geographical and socioeconomic levels. The incidence rates of some types of gastrointestinal cancer in higher sociodemographic index (SDI) countries tend to decrease or increase at a slower rate compared with the more significant rise observed in lower SDI countries. Another study on global gastrointestinal cancer also noted that the incidence tends to be concentrated in countries with higher SDI.2 In this global context, quantifying the inequalities in the burden of gastrointestinal cancers across countries is crucial for informing targeted strategies and optimising future efforts to reduce the global disparities in cancer burden. We use the SDI to represent the…

Pancreatic cancer is considered the third deadliest cancer in the US, resulting in more than 50 000 deaths each year, partially because tumors of the pancreas often go undetected until later stages. Although early-stage and localized pancreatic cancer has a much higher survival rate, there are no reliable US Food and Drug Administration–approved screening methods to detect tumors before they spread to the lymph nodes or other organs.

Nursing Up, per operatori salute rischio tumori del 10% in più

Nursing Up, per operatori salute rischio tumori del 10% in più

PaperClipThe adult pancreas protects against cancer by actively expelling genetically mutated cells. Pancreatic cancer starts with cells carrying KRAS mutations; however, it is not clear how some KRAS mutant cells override cell elimination mechanisms to survive in tissues.MethodsWe used an in vivo mouse model of sporadic tumorigenesis to induce Kras and/or Tp53 mutations in low numbers of cells in the adult pancreas. We monitored mutant cell fate over time using quantitative fluorescence imaging.

Studio, una bevanda al giorno aumenta il rischio di 5 volte

Studio, una bevanda al giorno aumenta il rischio di 5 volte

Introduction
Postoperative pancreatic fistula (POPF) is the most frequent complication after partial pancreatectomy, which is by definition associated with clinical consequences requiring changes in postoperative management. Despite numerous scientific efforts, effective procedures to prevent POPF are lacking. Obsidian ASG autologous platelet-rich fibrin matrix has been effectively applied to prevent anastomotic leakage following colorectal surgery. This study is the first to investigate the feasibility of using the sealant in pancreatic surgery.

Methods and analysis
25 consecutive patients scheduled for elective formal partial pancreatectomy due to any underlying disease fulfilling the eligibility criteria will be included. Obsidian ASG sealant prepared out of 120 mL of each patient’s whole blood will be applied to the pancreatic stump or the pancreatic anastomosis, respectively. The primary endpoint is the feasibility of the procedure, for example, the proportion of patients undergoing successful trial intervention. Secondary endpoints comprise safety and surgical outcome parameters including rate and severity of POPF as well as further pancreas-specific complications as defined by the International Study Group of Pancreatic Surgery during 90 days after surgery. Patients will be matched with a historic collective in a 1:2 ratio to gain first data on efficacy.

Ethics and dissemination
This trial and the associated study protocol (V.1.1.1, date 26 March 2024) were approved by the institution’s ethics committee (reference number 2191/2023). All trial procedures are performed in accordance with the International Council for Harmonisation harmonised tripartite guideline on Good Clinical Practice and the ethical principles of the Declaration of Helsinki. After completion of the study, results will be published in due course.

Trial registration number
The trial was registered in the German Clinical Trials Register on 6 May 2024 (DRKS-ID: DRKS00034052).

Per la prevenzione del cancro dell’intestino

Per la prevenzione del cancro dell’intestino